PDCD1 and non-small cell lung carcinoma: To further evaluate the impact of masking on QoL, we compared the effect of open-label trials versus double-blind trials in patients with NSCLC who underwent PD-1/PD-L1 inhibitors and chemotherapy in the QLQ-C30.